| Chapter 368 |
| 2026 -- H 8582 SUBSTITUTE A Enacted 06/22/2026 |
| A N A C T |
| RELATING TO INSURANCE -- PHARMACY FREEDOM OF CHOICE--FAIR COMPETITION AND PRACTICES |
Introduced By: Representatives Caldwell, and Solomon |
| Date Introduced: May 26, 2026 |
| It is enacted by the General Assembly as follows: |
| SECTION 1. Sections 27-29.1-1, 27-29.1-2, 27-29.1-7, 27-29.1-10 and 27-29.1-11 of the |
| General Laws in Chapter 27-29.1 entitled "Pharmacy Freedom of Choice — Fair Competition and |
| Practices" are hereby amended to read as follows: |
| 27-29.1-1. Definitions. |
| For purposes of this chapter, the following terms shall mean: |
| (1) “Director” shall mean the director of the department of business regulation. |
| (2) “Eligible bidder” shall mean a retail pharmacy, community pharmacy, or pharmacy |
| department registered pursuant to chapter 19.1 of title 5, irrespective of corporate structure or |
| number of locations at which it conducts business, located within the geographical service area of |
| a carrier and willing to bid for participation in a restricted pharmacy network contract. |
| (3)(2) “Insured” or "covered individual" shall mean any person who is entitled to have |
| pharmacy services paid by an insurer pursuant to a policy, certificate, contract, or agreement of |
| insurance or coverage. |
| (4)(3) “Insurer” shall mean an insurance carrier as defined in chapters 18, 19, 20, and 41 |
| of this title. |
| (5)(4) “Nonrestricted pharmacy network” shall mean a network that permits any pharmacy |
| to participate on substantially uniform terms and conditions established by an insurer or pharmacy |
| benefits manager pharmacy benefit manager. |
| (5) "Health insurance commissioner" or "commissioner" shall mean the office of health |
| insurance commissioner. |
| (6) “Pharmacy benefits manager” "Pharmacy benefit manager" or "PBM" shall mean any |
| person or entity who or that is not licensed in Rhode Island as an insurer and that develops or |
| manages pharmacy benefits, pharmacy network contracts, or the pharmacy benefit bid process have |
| the meaning provided in § 27-19-26.2. |
| (7) “Pharmacy benefit management services” shall mean the management or |
| administration of prescription drug benefits for an insurer, directly or through another entity, and |
| regardless of whether the pharmacy benefit manager and the insurer are related, or associated by |
| ownership, common ownership, organization or otherwise. Such management or administration |
| includes, but is not limited to: |
| (i) The administration or management of prescription drug benefits; |
| (ii) Claims processing, retail network management, or payment of claims to pharmacies for |
| dispensing prescription drugs; |
| (iii) Clinical or other formulary or preferred drug list development or management; |
| (iv) Negotiation or administration of rebates, discounts, payment differentials, or other |
| incentives, for the inclusion of particular prescription drugs in a particular category or to promote |
| the placement of particular prescription drugs on a formulary or preferred drug list; |
| (v) Patient compliance, therapeutic intervention, or generic substitution programs; |
| (vi) Disease management; |
| (vii) Drug utilization review or prior authorization; |
| (viii) Adjudication of appeals or grievances related to prescription drug coverage; |
| (ix) Contracting with network pharmacies; and |
| (x) Controlling the cost of covered prescription drugs. |
| (7)(8) “Restricted pharmacy network” shall mean an arrangement for the provision of |
| pharmaceutical drug services to insureds that under the terms of an insurer’s policy, certificate, |
| contract, or agreement of insurance or coverage requires an insured or creates a financial incentive |
| for an insured to obtain prescription drug services from one or more participating pharmacies that |
| have entered into a specific contractual relationship with the carrier. |
| (9) "Spread pricing" shall mean any amount charged or claimed by a pharmacy benefit |
| manager for a prescription drug that exceeds the amount paid by the pharmacy benefit manager to |
| a pharmacy or pharmacist for the dispensing of the prescription drug. |
| 27-29.1-2. Requirement for availability and accessibility of pharmacy services. |
| In accordance with § 23-17.13-3 [repealed], an An insurer must demonstrate to the director |
| health insurance commissioner of health the willingness and potential ability to ensure that |
| pharmacy services will be provided in a manner to ensure both availability and accessibility of |
| adequate personnel and facilities and in a manner enhancing availability, accessibility, and |
| continuity of service. |
| 27-29.1-7. Regulation of pharmacy benefit managers. |
| (a) Pharmacy benefits managers Pharmacy benefit manager shall be included within the |
| definition of third-party administrator under chapter 20.7 of this title and shall be regulated in |
| accordance with chapter 84 of this title as such. The annual report filed by third-party administrators |
| with the department of business regulation shall include: contractual language that provides a |
| complete description of the financial arrangements between the third-party administrator and each |
| of the insurers covering benefit contracts delivered in Rhode Island; and if the third-party |
| administrator is owned by or affiliated with another entity or entities, it shall include an |
| organization chart and brief description that shows the relationships among all affiliates within a |
| holding company or otherwise affiliated. The reporting shall be in a format required by the director |
| and filed with the department as a public record as defined and regulated under chapter 2 of title |
| 38. |
| (b) A pharmacy benefit manager shall not substitute or cause the substitution of one |
| prescription drug for another in dispensing a prescription including, but not limited to, a generic or |
| therapeutically equivalent drug, or alter or cause the altering of the terms of a prescription, without |
| the approval of the prescriber or as explicitly required or permitted by law, including regulations |
| of the health insurance commissioner or board of pharmacy and department of health. |
| (c) No pharmacy benefit manager shall, with respect to contracts between such pharmacy |
| benefit manager and a pharmacy or, alternatively, such pharmacy benefit manager and a pharmacy's |
| contracting agent including, but not limited to, a pharmacy services administrative organization: |
| (1) Prohibit or penalize a pharmacist or pharmacy from disclosing to an individual |
| purchasing a prescription medication or service information regarding: |
| (i) The cost of the prescription medication or service to the individual, or the cost of the |
| prescription medication or service to the pharmacy and the pharmacy's reimbursement for that |
| prescription medication or service; or |
| (ii) The availability of any therapeutically equivalent alternative medications or alternative |
| methods of purchasing the prescription medication including, but not limited to, paying a cash |
| price; or |
| (2) Charge or collect from an individual a copayment that exceeds the total submitted |
| charges by the pharmacy for which the pharmacy is paid. If an individual pays a copayment, the |
| pharmacy shall retain the adjudicated costs and the pharmacy benefit manager shall not redact or |
| recoup the adjudicated cost. |
| (d) A pharmacy benefit manager, with respect to contracts between a pharmacy benefit |
| manager and a pharmacy or, alternatively, a pharmacy benefit manager and a pharmacy's |
| contracting agent including, but not limited to a pharmacy services administrative organization, |
| shall include a reasonable process to appeal, investigate and resolve disputes regarding multi-source |
| generic drug pricing. The appeals process shall include the following provisions: |
| (1) The right to appeal by the pharmacy and/or the pharmacy's contracting agent shall be |
| limited to fifteen (15) days following the initial claim submitted for payment; |
| (2) A telephone number through which a network pharmacy may contact the pharmacy |
| benefit manager for the purpose of filing an appeal and an electronic mail address of the individual |
| who is responsible for processing appeals; |
| (3) The pharmacy benefit manager shall send an electronic mail message acknowledging |
| receipt of the appeal. The pharmacy benefit manager shall respond in an electronic message to the |
| pharmacy and/or the pharmacy's contracting agent filing the appeal within fifteen (15) days |
| indicating its determination. If the appeal is determined to be valid, the maximum allowable cost |
| for the drug shall be adjusted for the appealing pharmacy effective as of the date of the original |
| claim for payment. The pharmacy benefit manager shall require the appealing pharmacy to reverse |
| and rebill the claim in question in order to obtain the corrected reimbursement; |
| (4) If an update to the maximum allowable cost is warranted, the pharmacy benefit manager |
| or insurer shall adjust the maximum allowable cost of the drug effective for all similarly situated |
| pharmacies in its network in the state effective no later than one day after the date the appeal was |
| determined to be valid; and |
| (5) If an appeal is denied, the pharmacy benefit manager shall provide the reason for the |
| denial and identify the national drug code of a therapeutically equivalent drug, as determined by |
| the federal Food and Drug Administration, that is available and in adequate supply for purchase by |
| pharmacies in this state from wholesalers at a price which is equal to or less than the maximum |
| allowable cost for that drug as determined by the pharmacy benefit manager. |
| 27-29.1-10. Costs of enforcement. |
| The total cost of the enforcement under this chapter of §§ 27-29.1-3 and 27-29.1-8 shall be |
| borne by the pharmacy benefits manager(s) pharmacy benefit manager(s) and/or the insurer(s) |
| against whom the complaint investigation, examination or enforcement action is made on an equal |
| basis and shall include, without limitation, the following expenses: |
| (1) One hundred fifty percent (150%) of the total salaries and benefits paid to the personnel |
| of the department of business regulation office of health insurance commissioner engaged in the |
| enforcement less any salary reimbursement; |
| (2) All reasonable technology costs related to the enforcement process. Technology costs |
| shall include the actual cost of software and hardware utilized in the enforcement process and the |
| cost of training personnel in the proper use of the software or hardware; |
| (3) All necessary and reasonable education and training costs incurred by the state to |
| maintain the proficiency and competence of the enforcing personnel. All these costs shall be |
| incurred in accordance with the appropriate state of Rhode Island regulations, guidelines, and |
| procedures.; and |
| (4) Any reasonable expenses of any experts, consultants, and contractors retained by the |
| health insurance commissioner. |
| 27-29.1-11. Evaluation report. |
| The health insurance commissioner, pursuant to § 42-14.5-1, shall evaluate the impact of |
| nonrestricted pharmacy networks pharmacy benefit manager practices and operations on health |
| insurance costs in Rhode Island and shall submit a report of findings to the joint legislative |
| committee on health care oversight on or before May 1, 2005 and recommendations to the general |
| assembly on or before March 31, 2027. |
| SECTION 2. Chapter 27-29.1 of the General Laws entitled "Pharmacy Freedom of Choice |
| — Fair Competition and Practices" is hereby amended by adding thereto the following section: |
| 27-29.1-12. Duty, accountability, and transparency of pharmacy benefit managers. |
| (a)(1) The pharmacy benefit manager shall have a duty and obligation to perform pharmacy |
| benefit management services with care, skill, prudence, diligence, and professionalism. |
| (2) A pharmacy benefit manager interacting with a covered individual shall have the same |
| duty to a covered individual as the insurer for whom it is performing pharmacy benefit management |
| services. |
| (3) A pharmacy benefit manager shall have a duty of good faith and fair dealing with all |
| parties including, but not limited to, covered individuals and pharmacies, with whom it interacts in |
| the performance of pharmacy benefits management services. |
| (b) All funds received by the pharmacy benefit manager in relation to providing pharmacy |
| benefit management services shall be received by the pharmacy benefit manager in trust and shall |
| be used or distributed only pursuant to the pharmacy benefit manager's contract with the insurer or |
| applicable law; including any administrative fee or payment to the pharmacy benefit manager |
| expressly provided for in the contract to compensate the pharmacy benefit manager for its services. |
| Any funds received by the pharmacy benefit manager through spread pricing shall be subject to |
| this section. |
| (c) Beginning August 1, 2027, a pharmacy benefit manager shall provide to an insurer for |
| whom it is providing pharmacy benefit services: |
| (1) Any pricing discounts, rebates of any kind, inflationary payments, credits, clawbacks, |
| fees, grants, chargebacks, reimbursements, or other benefits received by the pharmacy benefit |
| manager. The insurer shall have access to all financial and utilization information of the pharmacy |
| benefit manager in relation to pharmacy benefit management services provided to the insurer; |
| (2) The terms and conditions of any contract or arrangement between the pharmacy benefit |
| manager and any party relating to pharmacy benefit management services provided to the insurer |
| including, but not limited to, dispensing fees paid to the pharmacies; and |
| (3) Any activity, policy, practice, contract or arrangement of the pharmacy benefit manager |
| that directly or indirectly presents any conflict of interest with the pharmacy benefit manager's |
| relationship with or obligation to the insurer. |
| (d) Beginning August 1, 2028, reports required to be provided under the Consolidated |
| Appropriation Act of 2026, and subsequent regulations, shall be deemed sufficient to comply with |
| the requirements of this subsection. |
| (e) Any information required to be disclosed by a pharmacy benefit manager to an insurer |
| under this section that is reasonably designated by the pharmacy benefit manager as proprietary or |
| trade secret information shall be kept confidential by the insurer, except as required or permitted |
| by law, including disclosure necessary to prosecute or defend any legitimate legal claim or cause |
| of action. Designation of information as proprietary or trade secret information under this |
| subsection shall have no effect on the obligations of any pharmacy benefit manager or insurer to |
| provide that information to the office of health insurance commissioner, provided any such |
| information provided to the office of health insurance commissioner shall be confidential and |
| exempt from disclosure under § 38-2-2. |
| 27-29.1-13. Rules and regulations. |
| The health insurance commissioner shall promulgate rules and regulations necessary to |
| effectuate the purpose of this chapter, including, defining, limiting, and relating to the duties, |
| obligations, requirements and other provisions relating to pharmacy benefit managers. |
| SECTION 3. This act shall take effect on January 1, 2027. |
| ======== |
| LC006502/SUB A |
| ======== |